India: Cadila Healthcare settles patent litigation related to Livalo tablets

February 6, 2017

On January 17, 2017, Cadila Healthcare declared that it has settled all outstanding patent infringement litigation filed by Kowa Pharmaceuticals and Nissan Chemical regarding the cholesterol drug Livalo (pitavastatin calcium).

India’s major drug Firm Cadila Healthcare and its subsidiary Zydus Pharmaceutical (USA) Inc., has finalized an agreement with Kowa Company, Kowa Pharmaceutical American Inc. and Nissan Chemical Industries Ltd.

Under the terms of finalized agreement, Kowa and Nissan grants Cadila’s Zydus Pharmaceuticals unit a license to market a generic version of Livalo beginning from May 2, 2023, or earlier under certain circumstances.

Livalo Tablets helps to reduce the following:

  • Total cholesterol
  • Low-density lipoprotein cholesterol
  • Apo-lipoprotein B
  • Triglycerides
  • To increase HDL-C in adult patients with primary hyperlipidemia

These tablets are indicated as an adjunctive therapy to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia.


For more information please contact us at :